Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics firm Biocartis and Abbott today announced a collaboration to develop and commercialize companion diagnostic tests for use on Biocartis' Idylla system.

Under the terms of the deal, the firms will leverage Biocartis' and Abbott's regulatory, scientific, and commercialization expertise, and in partnership with pharmaceutical companies, they will create biomarker panels for use on Idylla where each biomarker in the panel has known clinical significance.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.